Early Development and The Dose Selection in the Immune-oncology

The Effective Statistician - in association with PSI

المحتوى المقدم من Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry, Alexander Schacht, Benjamin Piske, and Leaders in the pharma industry. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry, Alexander Schacht, Benjamin Piske, and Leaders in the pharma industry أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

2M ago 21:59

AAC•منزل الحلقة

Interview with Teppo Huttunen

Key points:

Dose Selection Challenge
Limitations of 3+3 Design
BOIN Design
Backfilling
Efficacy vs. Safety
Statisticians’ Role
Practical Challenges
FDA Guidance
Cross-Functional Approach
Industry Trends
Cost & Timeline Estimation

Understanding dose selection in immune-oncology is crucial for developing safer and more effective treatments, and statisticians play a central role in driving these decisions.

In this episode, Teppo shares practical insights into overcoming the limitations of traditional methods and adopting more flexible approaches like the BOIN design.

If you want to stay ahead in oncology research and learn how to balance safety, efficacy, and practical challenges in dose optimization, this episode is a must-listen!

424 حلقات

#Natural Sciences #Statistics #Biostatistics #Pharmaceutical #Benjamin Piske #Alexander Schacht #Leaders in the pharma industry #Data Science #Science #Psy